WASHINGTON, D.C. — In a move that has already rattled Wall Street and divided the medical community, the U.S. Food and Drug Administration has appointed Dr. Vinay Prasad—an oncologist ...

Government advisers are meeting Thursday to decide if COVID-19 vaccines need updating to improve protection this fall and ...

The Trump administration said Tuesday it will limit approval for seasonal COVID-19 shots to seniors and others at high risk ...

NEW ORLEANS — Greetings from the home stretch of American Society of Gene and Cell Therapy conference, where everyone is still talking about Baby KJ and no one wants to talk about Vinay Prasad.

And among the biggest questions facing the gene therapy field is what stance Vinay Prasad, the fiery hematologist and frequent pharma critic who replaced him, will take toward such rare disease ...

The controversial appointment of oncologist Vinay Prasad — an outspoken critic of the pharmaceutical industry and US health agencies — to a key role within the Food and Drug Administration was ...

WASHINGTON (AP) — Dr. Vinay Prasad, a prominent critic of the pharmaceutical industry and the Food and Drug Administration, has been named to oversee the agency’s program for vaccines and ...

You can reach reporter Mike Francis at [email protected]. FILE - Dr. Vinay Prasad at Oregon Health & Science University, Nov. 22, 2016. Prasad was named director of the U.S. Food and Drug ...

To hear Vinay Prasad tell it, U.S. healthcare is too ready to intervene unnecessarily, use prescription drugs without sufficient evidence of their benefit and put patients at risk of side effects ...

You can reach Lizzy on Signal at lizzylaw.53. WASHINGTON — In his first address to FDA staff on Wednesday, Vinay Prasad emphasized his commitment to evidence, his admiration for agency employees ...

Prasad has questioned COVID-19 recommendations for children because they face lower risks from the virus than older people and those with weakened immune systems. HealthDay News — The US Food ...

Dr. Vinay Prasad has been tasked to head the FDA’s biologics division Prasad has criticized the U.S. government's response to COVID-19 His new role has caused biotech stocks to drop more than 5% ...